1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,890 | 1,920 | 13.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.06. | JUNSHI BIO (01877): FORM OF PROXY FOR THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 26 JUNE 2026 | 1 | HKEx | ||
| 05.06. | JUNSHI BIO (01877): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 05.06. | JUNSHI BIO (01877): 2025 AGM CIRCULAR | - | HKEx | ||
| 05.06. | JUNSHI BIO (01877): CONNECTED TRANSACTION - ENTERING INTO OF THE JOINT VENTURE AGREEMENT | - | HKEx | ||
| 05.06. | JUNSHI BIO (01877): CLOSURE OF REGISTER OF MEMBERS OF H SHARES | 2 | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 05.06. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON CHANGE IN SHAREHOLDING STRUCTURE OF IMPLEMENTING ... | 1 | HKEx | ||
| 05.06. | JUNSHI BIO (01877): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 05.06. | JUNSHI BIO (01877): RE-DESIGNATION OF DIRECTOR RETIREMENT UPON EXPIRY OF TERM AND PROPOSED ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHANGE IN COMPOSITION ... | 2 | HKEx | ||
| 27.05. | JUNSHI BIO Toripalimab Combined With Chemotherapy Clinical Trial Reaches Final Study Endpoints | 2 | AASTOCKS | ||
| 27.05. | Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC | 663 | GlobeNewswire (Europe) | SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 27.05. | Junshi Biosciences completes phase III lung cancer study | 2 | Investing.com | ||
| 26.05. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - TORIPALIMAB IN COMBINATION WITH CHEMOTHERAPY AS PERIOPERATIVE TREATMENT FOR RESECTABLE STAGE II-III NSCLC ... | - | HKEx | ||
| 22.05. | JUNSHI BIO Toripalimab Injection Approved in Mainland for 13th Indication | 2 | AASTOCKS | ||
| 21.05. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL OF THE SUPPLEMENTAL NEW DRUG APPLICATION OF TORIPALIMAB FOR THE FIRST-LINE TREATMENT OF HER2 EXPRESSING ... | 5 | HKEx | ||
| 21.05. | Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma | 341 | GlobeNewswire (Europe) | SHANGHAI, May 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 27.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2026 FIRST QUARTERLY REPORT | - | HKEx | ||
| 27.04. | JUNSHI BIO (01877): PROPOSED ADOPTION OF THE 2026 A SHARE EMPLOYEE STOCK OWNERSHIP SCHEME | 1 | HKEx | ||
| 27.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RESOLUTIONS OF THE NINETEENTH MEETING ... | - | HKEx | ||
| 27.04. | JUNSHI BIO (01877): 2025 ANNUAL REPORT | - | HKEx | ||
| 23.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE PLAN FOR THE REDUCTION IN THE SHAREHOLDING ... | 1 | HKEx |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,95 | +1,43 % | Zelltherapien rücken in den Mittelpunkt: Warum Mesoblast von einem grundlegenden Wandel in der Biotechnologie profitieren könnte | ||
| OCUGEN | 1,050 | 0,00 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 25,150 | +1,21 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer | Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval
SAN DIEGO, June 11, 2026 /PRNewswire/... ► Artikel lesen | |
| INFLARX | 1,388 | 0,00 % | ANALYSE: InflaRx NV: Könnte die Aktie jetzt komplett einbrechen? - Was Sie über das Wochenende vorbereiten sollten | ||
| EDITAS MEDICINE | 2,180 | +0,93 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 13,080 | -1,06 % | Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy | ||
| CARDIOL THERAPEUTICS | 0,907 | +0,44 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BASILEA | 54,10 | -0,18 % | David Veitch, CEO Basilea, im Interview | von Robert Jakob Moneycab.com: Herr Veitch, Basilea's Cresemba, ein Arzneimittel gegen Sporenpilze, macht mittlerweile weltweit rund 750 Millionen Dollar Umsatz. Wieviel davon schlägt auf die bottom... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 64,04 | -0,59 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 7,960 | -4,07 % | Prediction: I think Telix shares could double in value in 2026. Here's why | ||
| ONCO-INNOVATIONS | 0,471 | -2,89 % | Onco-Innovations meldet Start des Programms zur API-Prozessentwicklung und Zwischenprodukt-Skalierung für seine proprietäre PNKP-Inhibitor-Technologie | Vancouver, Kanada - 9. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich, den Beginn der Prozessentwicklung... ► Artikel lesen | |
| TWIST BIOSCIENCE | 65,86 | 0,00 % | Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains? | ||
| REPLIGEN | 114,75 | +1,64 % | Repligen Corporation: Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance | First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-yearReiterating FY26... ► Artikel lesen | |
| UNIQURE | 24,000 | +0,84 % | uniQure Inc.: uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates | ~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~
~ Progressing AMT-130 toward expected UK regulatory submission; MAA on... ► Artikel lesen | |
| REVOLUTION MEDICINES | 133,00 | +0,08 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen |
SHANGHAI JUNSHI BIOSCIENCES CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,080 (+4,42 %) liegt der Kurs bei 1,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.